Vascular Targeting Antibody Production Service
Background Service Workflow Highlights Published Data FAQs Contact
Are you currently facing challenges in antibody development, such as identifying effective targets within the tumor vasculature or developing highly specific antibodies that can overcome drug resistance? Our vascular targeting antibody production service helps you accelerate oncology drug discovery and develop highly specific antibodies against tumor blood vessels through advanced recombinant DNA technology and innovative protein engineering techniques.
Introduction
Angiogenesis, the generation of new vasculature, is essential for the progression, invasion, and dissemination of solid tumors. The resulting tumor-associated vessels are frequently structurally aberrant and permeable, fostering a detrimental microenvironment and impairing the effective transport of therapeutics. Vascular targeting antibodies offer a powerful therapeutic strategy by specifically binding to and disrupting these essential tumor vessels or the pro-angiogenic factors that drive their formation.
Fig.1 The advancement of carcinogenesis via angiogenesis.1,3
Vascular Targeting Antibody Production Service at Creative Biolabs
At Creative Biolabs, we understand the critical role of tumor vasculature in cancer growth, invasion, and metastasis, as well as its contribution to therapeutic resistance. Our vascular targeting antibody production service is meticulously designed to provide you with high-quality, highly specific antibodies that can effectively target key components of the tumor blood vessels, disrupting their function, enhancing drug delivery, and ultimately improving therapeutic outcomes.
This approach aims to starve tumors of vital nutrients and oxygen, normalize the tumor microenvironment to improve drug penetration, and potentially enhance anti-tumor immune responses, building on extensive research into angiogenic signaling pathways.
We offer a comprehensive solution from target identification to antibody characterization and in vivo analysis, ensuring your project's success. As part of this solution, we provide biodistribution and pharmacokinetic (PK) characterization, including:
- Radio-labeling Services: Conjugating antibodies with radioisotopes for in vivo imaging to precisely track their distribution and accumulation in target tissues.
- PK/PD Analysis Support: Providing analytical services to evaluate the in vivo half-life, clearance, and tissue distribution of antibody therapeutics.
Service Process
Key Advantages
- Customized Antibody Development Strategies: Flexible, bespoke approaches from antigen design and immunization to advanced engineering, aligned with your vascular target and therapeutic goals.
- Expert Upstream & Downstream Process Development: Optimize antibody production: efficient cell line development and fermentation (upstream); high-yield purification and strict quality control (downstream) for superior quality.
- Scalable Production Capabilities: State-of-the-art facilities with diverse bioreactor capacities meet needs from early research to large-scale preclinical studies, enabling seamless scaling.
- Rigorous Quality-by-Design (QbD) and Process Analytical Technologies (PAT): QbD principles and advanced PAT ensure consistent quality, process control, and regulatory compliance; strict aseptic verification throughout production.
- Comprehensive Strain Stability & Cell Bank Management: Comprehensive evaluation of strain provenance combined with stringent cell bank management ensures the long-term genetic and phenotypic stability of antibody-producing cell lines, enabling consistent and reproducible manufacturing, including preparatory cultivation phases.
- Optimized Gene Expression & Culture Conditions: Optimize codon usage for expression in microorganisms/mammalian systems; fine-tune culture conditions (batch, fed-batch, continuous) to maximize antibody yield.
- Certified Production & Aseptic Control: Compliant processes with stringent aseptic verification and HACCP adherence ensure safety/purity for preclinical/clinical use.
- Dedicated Quality Control & Environmental Responsibility: High-standard quality control tools ensure consistent product quality; commitment to sustainable practices and environmental protection.
Data Display
Summary: This study explores ABL001, a bispecific antibody targeting VEGF and DLL4, in combination with chemotherapy (paclitaxel or irinotecan) in xenograft models. It shows ABL001 alone inhibits tumor progression in various gastric and colon cancer models. Combined with chemotherapy, it synergistically suppresses tumor growth via more potent tumor vessel regression (reduced CD31, VEGFR-2, DLL4) and increased apoptotic cells (activated caspase-3).
Conclusions: ABL001 with chemotherapy enhances anti-tumor effects by anti-angiogenesis and apoptosis induction, supporting its clinical potential.
Fig.2 Immunofluorescence technique detects the expression of DLL4 in tumor blood vessels.2,3
FAQs
What types of vascular targets can your service accommodate?
Our service is highly versatile and can accommodate a wide range of vascular targets, including but not limited to growth factors (e.g., VEGF, FGF), their receptors (e.g., VEGFRs, FGFRs), endothelial cell surface markers, and other molecules involved in angiogenesis and vascular integrity. We encourage you to discuss your specific target with our scientific team to explore the best approach.
How does vascular targeting enhance overall cancer therapy compared to direct tumor cell targeting?
While direct tumor cell targeting is crucial, vascular targeting offers complementary benefits by disrupting the tumor's blood supply, leading to oxygen and nutrient deprivation. This can also normalize tumor vessels, improving the delivery of conventional chemotherapies and immunotherapies, and reducing metastasis. It addresses mechanisms of resistance that direct tumor cell targeting alone might miss.
What are the advantages of using a bispecific antibody approach for vascular targeting?
A bispecific antibody approach, like targeting both VEGF and DLL4, offers significant advantages by simultaneously modulating multiple pathways critical for angiogenesis and vascular function. This can lead to more potent anti-tumor effects, overcome compensatory resistance mechanisms, and potentially enhance immune cell infiltration, as demonstrated in preclinical studies.
Why Choose Us?
Choosing Creative Biolabs for your vascular targeting antibody production needs means partnering with a leader in the field, renowned for our scientific rigor, innovative platforms, and commitment to client success.
Customer Reviews
"Using Creative Biolabs' vascular targeting antibody production service in our research has significantly improved the specificity of our therapeutic candidates, allowing us to precisely target critical vascular elements. The antibodies we received were of outstanding quality, and their detailed characterization reports saved us considerable in-house validation time. This precision is crucial for our work on overcoming drug resistance." - 2024, Dr. L*** W***
"The comprehensive characterization provided by Creative Biolabs for our vascular-targeting antibodies was invaluable. We gained deep insights into binding kinetics and functional activity, which is essential for advancing our preclinical studies. Their service offered a clear advantage over alternative providers, particularly in their rigorous quality control and attention to detail, ensuring reliable and reproducible results for our in vivo applications." - 2024, Dr. B*** R***
How to Contact Us
Ready to advance your oncology research with innovative vascular-targeting antibodies? Contact our expert team today to discuss your specific project requirements and discover how Creative Biolabs can help you achieve your goals.
Contact Our Team for More Information and to Discuss Your Project
References
- Liu, Zhen-Ling et al. "Angiogenic signaling pathways and anti-angiogenic therapy for cancer." Signal transduction and targeted therapy vol. 8,1 198. 11 May. 2023. DOI: https://doi.org/10.1038/s41392-023-01460-1
- Yeom, Dong-Hoon et al. "ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models." International journal of molecular sciences vol. 22,1 241. 29 Dec. 2020. DOI: https://doi.org/10.3390/ijms22010241
- Distributed under Open Access License CC BY 4.0, without modification.
For research use only. Not intended for any clinical use.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
